查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604756

自体免疫疾病治疗药物市场：按适应症、药物类别、分布划分 - 全球预测 2025-2030

Autoimmune Disease Drugs Market by Indication (Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases), Drug Class (Anti-Inflammatory, Antihyperglycemic, Immunosuppressants), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年自体免疫疾病治疗市值为1,087.1亿美元，预估2024年将达1,167.9亿美元，复合年增长率为7.52%，至2030年将达1,806.7亿美元。

自体免疫疾病治疗市场包括旨在治疗免疫系统错误攻击健康细胞的各种自体免疫疾病的药物的开发、生产和分销。这些药物对于对抗类风湿性关节炎、多发性硬化症和狼疮等慢性疾病以及改善患者的生活品质至关重要。由于遗传倾向、环境影响和生活方式改变等因素，全球自体免疫疾病的盛行率不断增加，推动了对自体免疫疗法的需求。这些药物的范围涵盖医院、诊所和居家医疗，最终使用者包括医疗机构和有持续治疗需求的个人。市场成长主要归功于生物技术的进步，导致生技药品和生物相似药等创新药物的开发。不断增长的医疗保健支出、患者意识和诊断能力也对市场扩张做出了重大贡献。潜在的机会在于新兴市场和透过药物基因组学实现的个人化医疗，这使得能够根据患者的基因谱进行客製化治疗。然而，市场面临着药品成本上涨、严格的法规环境以及自体免疫疾病的复杂性等挑战，这些挑战使治疗通讯协定变得复杂。此外，专利到期和生物相似药的出现可能会加剧竞争。创新可能发生在替代药物传输系统、研究微生物组在自体免疫反应中的作用以及开发副作用较少的药物等领域。製药公司和学术机构之间的合作研究可能会激发新的发现。了解市场的复杂性至关重要，因为它的特点是技术快速进步和不断变化的监管环境。寻求创新和主导的主要企业将能够透过投资研发、专注于策略联盟和优先考虑以患者为中心的方法，在这个充满活力的领域成功发展。

主要市场统计
基准年[2023] 1087.1亿美元
预计年份 [2024] 1167.9亿美元
预测年份 [2030] 1806.7亿美元
复合年增长率（%） 7.52%

市场动态：揭示快速发展的自体免疫疾病药物市场的关键市场洞察

供需的动态交互作用正在改变自体免疫疾病治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 类风湿性关节炎、格雷夫兹病和桥本甲状腺病等自体免疫疾病的盛行率增加
    • 人们对自体免疫疾病的认识不断增强
    • 完善政府支持、资助和报销政策
  • 市场限制因素
    • 与自体免疫疾病治疗药物相关的副作用
  • 市场机会
    • 后期管道药物的进展和可用性
    • 自体免疫疾病治疗的持续研究与技术创新
  • 市场挑战
    • 自体免疫疾病药物高成本

波特五力：驾驭自体免疫疾病药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解自体免疫疾病药物市场的外部影响

外部宏观环境因素在塑造自体免疫疾病治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解自体免疫疾病治疗药物市场的竞争状况

对自体免疫疾病治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵自体免疫疾病治疗市场供应商的绩效评估

FPNV定位矩阵是评估自体免疫疾病治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划自体免疫疾病治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对自体免疫疾病治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 自体免疫疾病类风湿性关节炎、格雷夫兹病和桥本氏症的发生率增加
      • 人们对自体免疫疾病的认识不断增强
      • 完善政府援助、资助和报销政策
    • 抑制因素
      • 与自体免疫疾病药物相关的副作用
    • 机会
      • 后期管道药物的进展和可用性
      • 自体免疫疾病治疗的持续研究与创新
    • 任务
      • 自体免疫疾病药物高成本
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章自体免疫疾病治疗药物市场（按适应症）

  • 1型糖尿病
  • 多发性硬化症
  • 罕见疾病
  • 风湿性疾病

第七章依药物类别分類的自体免疫疾病治疗药物市场

  • 发炎（药
  • 降血糖药
  • 免疫抑制剂
  • 干扰素
  • 非类固醇消炎剂

第八章自体免疫疾病治疗药物市场经销商

  • 医院药房
  • 网路商店
  • 零售药房

第九章北美和南美自体免疫疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区自体免疫疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲自体免疫疾病治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AESKU.GROUP GmbH & Co. KG
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • Biogenuix Medsystems Private Limited
  • bioMerieux SA
  • Exagen, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Werfen SA
Product Code: MRR-436901065FE5

The Autoimmune Disease Drugs Market was valued at USD 108.71 billion in 2023, expected to reach USD 116.79 billion in 2024, and is projected to grow at a CAGR of 7.52%, to USD 180.67 billion by 2030.

The autoimmune disease drugs market encompasses the development, production, and distribution of pharmaceuticals aimed at treating a variety of autoimmune conditions, where the immune system mistakenly attacks healthy cells. These drugs are vital as they address chronic illnesses such as rheumatoid arthritis, multiple sclerosis, and lupus, improving patient quality of life. The necessity for autoimmune drugs stems from increasing incidence rates of autoimmune disorders globally, heightened by factors such as genetic predisposition, environmental influences, and lifestyle changes. The application of these drugs spans hospitals, clinics, and home care settings, with end-users including healthcare facilities and individuals requiring ongoing treatment. Market growth is largely driven by advancements in biotechnology, leading to the development of innovative drugs such as biologics and biosimilars. Increasing healthcare spending, patient awareness, and diagnostic capabilities also contribute significantly to expanding the market. Potential opportunities lie in emerging markets and the personalization of medicine through pharmacogenomics, which allows for tailored treatments based on patient genetic profiles. However, the market faces challenges, including high drug costs, stringent regulatory environments, and the complexity of autoimmune diseases which can complicate treatment protocols. Moreover, patent expirations and the emergence of biosimilars can heighten competition. Innovation is likely to thrive in areas like alternative drug delivery systems, research on the microbiome's role in autoimmune responses, and developing drugs with fewer side effects. Collaborations between pharmaceutical companies and academic institutions could fuel new discoveries. Understanding the market's intricate nature is crucial, as it is characterized by rapid technological advancements and evolving regulatory landscapes. Companies aspiring to innovate and lead should invest in R&D, focus on strategic alliances, and prioritize patient-centric approaches to successfully navigate and capture growth in this dynamic field.

KEY MARKET STATISTICS
Base Year [2023] USD 108.71 billion
Estimated Year [2024] USD 116.79 billion
Forecast Year [2030] USD 180.67 billion
CAGR (%) 7.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autoimmune Disease Drugs Market

The Autoimmune Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of autoimmune diseases rheumatoid arthritis, graves and hashimoto's thyroid disease
    • Growing awareness of autoimmune diseases
    • Improved government assistance, funding, and reimbursement policies
  • Market Restraints
    • Associated side effects of autoimmune disease drugs
  • Market Opportunities
    • Advancements and availability of late-stage pipeline drugs
    • Ongoing research and innovations in autoimmune disease drugs
  • Market Challenges
    • High cost of autoimmune disease medications

Porter's Five Forces: A Strategic Tool for Navigating the Autoimmune Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autoimmune Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autoimmune Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autoimmune Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autoimmune Disease Drugs Market

A detailed market share analysis in the Autoimmune Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autoimmune Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autoimmune Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autoimmune Disease Drugs Market

A strategic analysis of the Autoimmune Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AESKU.GROUP GmbH & Co. KG, AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Biogenuix Medsystems Private Limited, bioMerieux S.A., Exagen, Inc., F. Hoffmann-La Roche AG, Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases, and Rheumatic Diseases.
  • Based on Drug Class, market is studied across Anti-Inflammatory, Antihyperglycemic, Immunosuppressants, Interferons, and Nonsteroidal Anti-Inflammatory Drugs.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of autoimmune diseases rheumatoid arthritis, graves and hashimoto's thyroid disease
      • 5.1.1.2. Growing awareness of autoimmune diseases
      • 5.1.1.3. Improved government assistance, funding, and reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects of autoimmune disease drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and availability of late-stage pipeline drugs
      • 5.1.3.2. Ongoing research and innovations in autoimmune disease drugs
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of autoimmune disease medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Diabetes Mellitus Type 1
  • 6.3. Multiple Sclerosis
  • 6.4. Rare Diseases
  • 6.5. Rheumatic Diseases

7. Autoimmune Disease Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Inflammatory
  • 7.3. Antihyperglycemic
  • 7.4. Immunosuppressants
  • 7.5. Interferons
  • 7.6. Nonsteroidal Anti-Inflammatory Drugs

8. Autoimmune Disease Drugs Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Stores
  • 8.4. Retail Pharmacies

9. Americas Autoimmune Disease Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autoimmune Disease Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autoimmune Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AESKU.GROUP GmbH & Co. KG
  • 3. AstraZeneca PLC
  • 4. Beckman Coulter, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. BioAgilytix Labs, LLC
  • 7. Biogenuix Medsystems Private Limited
  • 8. bioMerieux S.A.
  • 9. Exagen, Inc.
  • 10. F. Hoffmann-La Roche AG
  • 11. Novartis AG
  • 12. Pfizer, Inc.
  • 13. Sanofi S.A.
  • 14. Siemens Healthineers AG
  • 15. Thermo Fisher Scientific Inc.
  • 16. Trinity Biotech PLC
  • 17. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANTIHYPERGLYCEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023